Creating alternative incentives for pharmaceutical innovation
Lyles, A.
Clinical Therapeutics 28(1): 126-128
2006
ISSN/ISBN: 0149-2918 PMID: 16490586 DOI: 10.1016/s0149-2918(06)00021-x
Accession: 048680469
PDF emailed within 0-6 h: $19.90
Related References
Yanadori, Y; Cui, V 2013: Creating incentives for innovation? The relationship between pay dispersion in R&D groups and firm innovation performance Strategic Management Journal 34(12): 1502-1511Manso, G. 2017: Creating Incentives for Innovation California Management Review 60(1): 18-32
Yin, W. 2008: Market incentives and pharmaceutical innovation Journal of Health Economics 27(4): 1060-1077
Batabyal, A. 2005: Strong medicine: Creating incentives for pharmaceutical research on neglected diseases Journal of Agricultural and Environmental Ethics 18(4): 415-417
Kesselheim, A.S. 2010: Using market-exclusivity incentives to promote pharmaceutical innovation New England Journal of Medicine 363(19): 1855-1862
González, P.; Macho-Stadler, I.és.; Pérez-Castrillo, D. 2016: Private versus social incentives for pharmaceutical innovation Journal of Health Economics 50: 286-297
Conti, R.M.; Rosenthal, M.B. 2016: Pharmaceutical Policy Reform--Balancing Affordability with Incentives for Innovation New England Journal of Medicine 374(8): 703-706
Lietzan, E.; Acri née Lybecker, K.M.L. 2019: The innovation paradox: pharmaceutical marketing exclusivity and incentives for drug development Journal of Pharmaceutical Health Services Research 10(2): 169-175
Zhang, L.; Wang, J. 2021: Incentives to promote the US pharmaceutical innovation: empirical research based on the case of Epogen Drug Development and Industrial Pharmacy 2021: 1-14
Wardell, W.M.; Sheck, L.E. 1983: Is pharmaceutical innovation declining?: interpreting measures of pharmaceutical innovation and regulatory impact in the USA, 1950-1980 Rational Drug Therapy 17(1): 1-7
Santopietro, G.D. 1995: Raising environmental consciousness versus creating economic incentives as alternative policies for environmental protection Journal of Economic Issues 29(2): 517-524
Douglas, C.M.W.; Aith, F.; Boon, W.; de Neiva Borba, M.; Doganova, L.; Grunebaum, S.; Hagendijk, R.; Lynd, L.; Mallard, A.; Mohamed, F.A.; Moors, E.; Oliveira, C.C.; Paterson, F.; Scanga, V.; Soares, J.; Raberharisoa, V.; Kleinhout-Vliek, T. 2022: Social pharmaceutical innovation and alternative forms of research, development and deployment for drugs for rare diseases Orphanet Journal of Rare Diseases 17(1): 344
Russo, M.; Caloffi, A.; Rossi, F.; Righi, R. 2018: Innovation intermediaries and performance-based incentives: a case study of regional innovation poles Science and Public Policy 46(1): 1-12
Aagaard, A.; Lindgren, P. 2015: The Opportunities and Challenges of Persuasive Technology in Creating Sustainable Innovation and Business Model Innovation Wireless Personal Communications 81(4): 1511-1529
Ziegler, R. 2015: Justice and innovation – towards principles for creating a fair space for innovation Journal of Responsible Innovation 2(2): 184-200
Jörg Musiolik; Jochen Markard 2011: Creating and shaping innovation systems: Formal networks in the innovation system for stationary fuel cells in Germany Energy Policy 39(4): 1909-1922
Hebert, G.; Protlabarthe, S.; Tremblay, M.E.; Bussieres, J.F.; Bourdon, O. 2014: La pédiatrie, toujours exclue de l'innovation pharmaceutique ? - Is pediatrics excluded from pharmaceutical innovation? Archives de Pediatrie (Paris) 21(3): 245-250
Honig, P.; Zhang, L. 2019: Regulation and Innovation: Role of Regulatory Science in Facilitating Pharmaceutical Innovation Clinical Pharmacology and Therapeutics 105(4): 778-781
Grognet, J.M. 2003: L'innovation pharmaceutique marque-t-elle le pas ? : Le médicament est-il malade ? - Pharmaceutical innovation Biofutur (Puteaux) 239: 20-22
Aagaard, A. 2012: The Contribution of Innovation Strategy Development and Implementation in Active Facilitation of Pharmaceutical Front End Innovation Systemic Practice and Action Research 25(6): 457-477